PubMed Health⌕ Search

Biomedical subjects

S Gagey

Publications and source records attributed to S Gagey.

4 recordsLinked to original sources
PubMed1995

Twenty-four hour efficacy of two dose levels of a once daily sustained-release diltiazem formulation in stable angina: a placebo-controlled trial. The Dildurang Study Group.

1. This placebo-controlled study assessed once daily sustained-release (SR) diltiazem, 200 and 300 mg, in 182 stable angina patients with positive exercise test. 2. Exercise testing was performed at baseline after a 7 day placebo run-in period, and repeated after 7 days of treatment, 25.0 +/- 0.1 h postdose. 3. Diltiazem (200 and 300 mg) produced respectively a 68% and a 64% decrease in weekly angina episodes, and placebo a 15% decrease (P < 0.05). Similarly, both dose levels produced a 70% decrease in nitroglycerin consumption, whereas no difference was obtained with placebo (P < 0.01). The increase in time to ischaemic threshold was significantly superior for 200 mg and 300 mg diltiazem when compared with placebo (75.2 and 91.5 s respectively vs 47.0 s) (P < 0.05); increase in time to anginal threshold was also significantly greater for diltiazem when compared with placebo (84.6 and 85.9 s respectively vs 43.9 s) (P < 0.05). 4. Only one patient experienced worsening of angina and had to be withdrawn from the study. 5. This study demonstrates 200 and 300 mg SR diltiazem is effective when given once-a-day in the prophylaxis of stable exertional angina. This once daily formulation should improve patients' compliance and comfort.

Adult↗
PubMed1992

[Non invasive evaluation of cardiovascular effects of nebivolol in patients with cardiac insufficiency].

The results of several studies, mostly without controls, have suggested that betablockers, administered at progressively increasing doses, may be beneficial in cardiac failure. Based on this hypothesis, betablockers with a peripheral vasodilator effect, such as Nebivolol, could be particularly valuable in this indication. A preliminary study of its tolerance, haemodynamic and neurohormonal effects was carried out with a noninvasive methodology in 12 patients with cardiac failure in sinus rhythm, 8 men and 4 women (average age 53 +/- 12 years), all of whom had Class III or IV symptoms according to the NYHA Classification. The protocol had 2 phases: the first was an open phase during which Nebivolol was administered at a dose of 1 mg/day for 48 hours then 2.5 mg/day for 72 h. In the second phase, the patients were randomly separated into 2 groups, one to receive placebo and the other 2.5 mg for one week then 5 mg of Nebivolol for the 5 remaining weeks. The heart rate decreased significantly from 70 +/- 3 to 63 +/- 4 beats/min (p < 0.01) with Nebivolol 1 mg/day without further slowing at the 2.5 mg dosage. During the randomised phase, the heart rate remained stable in the Nebivolol group but increased to its initial value in the group given placebo. No aggravation of symptoms was observed in the Nebivolol group. No significant changes in cardiac output, parameters of cardiac loading or contractility could be demonstrated after 6 weeks' treatment. During submaximal exercise testing, plasma concentrations of catecholamines and atrial natriuretic factor tended to be higher with Nebivolol than with placebo.(ABSTRACT TRUNCATED AT 250 WORDS)

Adrenergic beta-Antagonists↗
PubMed1988

[Effect of the sinusal rate on experimental vagal atrial arrhythmia].

Factors that facilitate the occurrence of cholinergic atrial arrhythmias were studied on 16 rabbit biatrial preparations in spontaneous rhythm. Sinus cycle length and characteristics of the atrial action potential were measured by the microelectrode technique in the basal state, then in the presence of acetylcholine at a concentration of 1.4 x 10(-5) M. Induction of arrhythmia was attempted by programmed stimulation, using an increasing number of extrastimuli. In the presence of acetylcholine the sinus cycle length increased by 106 +/- 63 p. 100 (p less than 0.0001) and the action potential duration, measured at 90 p. 100 repolarization (APD90) decreased from 60 +/- 15 ms to 40 +/- 11 ms (p less than 0.001). Reentrant activities, which had not been found in the basal state, were induced in 5 preparations. Under acetylcholine the sinus cycle of inducible preparations was shorter than that of non inducible preparations (663 +/- 272 ms vs 1218 +/- 531 ms, p less than 0.05). The percentage of sinus cycle lengthening was significantly smaller in inducible preparations (54 +/- 31 p. 100 vs 129 +/- 60 p. 100, p less than 0.05). Although sinus cycle lengthening was different in the two types of preparations, the APD90 was shortened in the same proportions. The vulnerability of the preparations seemed to depend mainly on a frequency effect. Vagal atrial arrhythmias occurred with a relatively small reduction in sinus rhythm. It is probable that an overpotent vagal effect is less arrhythmogenic because of its more homogeneous action on tissues.

Acetylcholine↗